Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesIovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc.

PortfolioPortfolio WatchlistWatchlist
Company price
14.61 GBX 0.95 ( 6.95%)
Last update at 2026-10-27T16:39:00Z
VOLUME
29202
Market Cap
47810.33M

Momentum Score

…

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.67
Low
14.76
High
52 Week Price Range
1.57
Low
5.69
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Iovance Biotherapeutics develops tumor-infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors, with a focus on its lead candidate and follow-on programs. Long-term growth drivers include advancement of late-stage clinical data, potential regulatory approvals across indications, and scaling of complex manufacturing to support commercialization. Investors may find the company attractive because it targets high unmet needs in refractory solid tumors with a differentiated immunotherapy approach that could deliver durable responses.

Principal investment risks include pivotal clinical or regulatory setbacks, operational and cost challenges from autologous manufacturing scale-up, and the need for additional financing to support ongoing development and commercialization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
13.66
Dividend Yield
-
Revenue TTM
263.50M
Revenue Per Share
0.74
Gross Profit TTM
90.32M
Debt / Equity
0.13
ROE
-55.50%
Net Debt
-69.23M
ROCE
-51.39%
Diluted EPS TTM
-2.30

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -393.05M -375.00M -447.52M -395.89M -342.25M
Net income -390.98M -372.18M -444.04M -395.89M -342.25M
Selling general administrative - 51.80M 27.70M 104.10M 83.66M
Selling and marketing expenses - 101.22M 79.22M - -
Gross profit 54.38M 17.67M -9.57M - -
Ebit -398.21M -375.00M -460.56M -398.88M -342.70M
Ebitda -362.27M -331.40M -449.01M -389.57M -339.59M
Depreciation and amortization 35.94M 43.61M 11.55M 9.31M 3.11M
Operating income -398.21M -395.28M -460.56M -398.88M -342.70M
Other operating expenses 661.72M 559.35M 461.75M 399.35M 348.72M
Interest expense - - - - 0.00M
Income tax expense -2.07M -2.83M -3.48M - -
Total revenue 263.50M 164.07M 1.19M - -
Total operating expenses 452.59M 412.95M 450.99M 399.35M 348.72M
Cost of revenue 209.12M 146.40M 10.76M - -
Total other income expense net 5.16M 20.27M 13.04M 2.98M 0.45M
Net income applicable to common shares - - - -395.89M -342.25M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 913.17M 910.43M 780.35M 663.98M 777.33M
Intangible assets 279.32M 282.40M 229.26M - -
Other current assets 11.58M 12.38M 17.46M 7.27M 3.55M
Total liab 214.59M 200.02M 195.74M 164.34M 155.67M
Total stockholder equity 698.58M 710.40M 584.61M 499.64M 621.66M
Other current liab 111.16M 69.04M 61.63M 64.88M 61.82M
Common stock 0.02M 0.01M 0.01M 0.01M 0.01M
Retained earnings -2775.53M -2384.55M -2012.38M -1568.34M -1172.44M
Other assets - - - 6.62M 7.87M
Cash 163.08M 115.69M 114.89M 231.73M 78.23M
Total current liabilities 138.36M 122.34M 110.31M 91.48M 89.20M
Current deferred revenue - - 0.00M - -
Net debt -69.23M -57.43M -39.03M -231.73M -78.23M
Short term debt 5.04M 25.79M 15.55M - -
Short long term debt total 93.84M 58.26M 75.86M - -
Other stockholder equity 3457.65M 3095.99M 2594.45M 2067.97M 1794.09M
Property plant equipment - - - 178.25M 169.92M
Total current assets 442.69M 457.02M 307.85M 479.12M 507.96M
Net tangible assets - - - 499.63M 621.66M
Short term investments 133.90M 208.09M 164.98M 240.11M 426.18M
Net receivables 82.45M 69.34M 0.15M - -
Inventory 51.68M 51.52M 10.37M - -
Accounts payable 22.16M 27.51M 33.12M 26.60M 27.38M
Accumulated other comprehensive income 16.44M -1.05M 2.53M - -
Non currrent assets other 8.17M 0.37M 0.27M -178.25M -261.51M
Non current assets total 470.48M 453.41M 472.50M 178.25M 261.51M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - 276.88M 37.71M
Change to liabilities - - - 5.88M 6.98M
Total cashflows from investing activities 47.50M -96.41M -155.24M 256.45M 0.13M
Net borrowings - - - - 1.00M
Total cash from financing activities 300.77M 390.66M 462.96M 190.15M 239.27M
Change to operating activities - - - -8.78M 17.58M
Net income -390.98M -372.18M -444.04M -395.89M -342.25M
Change in cash 47.38M 0.81M -56.84M 153.85M 11.46M
Begin period cash flow 115.69M 114.89M 238.16M 84.31M 72.85M
End period cash flow 163.08M 115.69M 181.32M 238.16M 84.31M
Total cash from operating activities -302.41M -352.98M -361.82M -292.76M -227.94M
Depreciation 47.32M 43.61M 33.13M 21.14M 13.98M
Change to inventory -14.21M -39.92M -10.12M - -
Change to account receivables -13.11M -69.19M -0.15M - -
Sale purchase of stock - - -2.79M -2.65M -
Other cashflows from financing activities -7.06M -12.86M 465.75M 192.80M 239.27M
Change to netincome - - - 84.89M 75.78M
Capital expenditures 33.84M 11.07M 22.29M 20.43M 37.57M
Change in working capital -24.27M -122.56M -11.35M - -
Stock based compensation - - 62.62M 84.02M 69.77M
Other non cash items 67.58M 100.98M 1.29M -2.02M 30.57M
Free cash flow -336.24M -364.05M -384.11M -313.18M -265.51M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0JDK
Iovance Biotherapeutics Inc.		 0.95
6.95%		 14.61 - - 1.81 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Iovance Biotherapeutics Inc.

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

825 Industrial Road, San Carlos, CA, United States, 94070

650 260 7120

https://www.iovance.com

975

Name Title Year Born
Dr. Frederick G. Vogt Esq., J.D., Ph.D. Interim CEO, Pres, Gen. Counsel & Corp. Sec. 1974
Mr. Jean-Marc Bellemin M.B.A. Chief Financial Officer & Principal Accounting Officer 1972
Dr. Igor P. Bilinsky Chief Operating Officer 1973
Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer 1967
Ms. Sara Pellegrino VP of Investor Relations & PR NA
Ms. Tracy Winton Sr. VP of HR NA
Mr. Howard B. Johnson M.B.A. Chief Bus. Officer 1960
Mr. James Ziegler M.B.A. Exec. VP of Commercial NA
Mr. Madan Jagasia Exec. VP of Medical Affairs NA
Dr. Raj K. Puri M.D., Ph.D. Exec. VP of Regulatory Strategy & Translational Medicine NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…